Advm Stock News

REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,

REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in the Auditory and Ophthalmology panel discussion at the 42 nd Annual Cowen Healthcare Conference on Monday, March 7, 2022, at 2:10 p.m. ET.

Adverum Biotechnologies (ADVM) has appointed ophthalmologist Richard Beckman, M.D., as the company''s new chief medical officer. Most recently, Dr

- Dr. Beckman, a board-certified ophthalmologist, brings 30 years of experience in ophthalmology, drug development and retinal diseases including wet age-related macular degeneration -

- Dr. Beckman, a board-certified ophthalmologist, brings 30 years of experience in ophthalmology, drug development and retinal diseases including wet age-related macular degeneration -

NEW YORK , Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, EVFM, ADVM, FREY, and PL. Full story available on Benzinga.com

Adverum Biotechnologies Inc (ADVM) shares closed today at 1.2% above its 52 week low of $1.66, giving the company a market cap of $164M. The stock is currently down 4.5% year-to-date, down 85.9% over the past 12 months, and down 44.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 15.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 185.7% The company's stock price performance over the past 12 months lags the peer average by 185.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Adverum Biotechnologies Inc (ADVM) shares closed today at 1.2% above its 52 week low of $1.66, giving the company a market cap of $164M. The stock is currently down 4.5% year-to-date, down 86.0% over the past 12 months, and down 44.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 15.9% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 5.6% lower than its 5-day moving average, 7.0% lower than its 20-day moving average, and 18.3% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 442.5% The company's stock price performance over the past 12 months lags the peer average by 187.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,

Adverum Biotechnologies (NASDAQ:ADVM) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Valuation and Earnings This table compares Adverum Biotechnologies and Acumen Pharmaceuticals revenue, earnings per share []

Zacks Investment Research upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a hold rating to a buy rating in a research note released on Monday morning, Zacks.com reports. They currently have $2.00 target price on the biotechnology companys stock. According to Zacks, Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and []

Analysts expect that Adverum Biotechnologies, Inc. (NASDAQ:ADVM) will report earnings of ($0.42) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Adverum Biotechnologies earnings, with the lowest EPS estimate coming in at ($0.43) and the highest estimate coming in at ($0.41). Adverum Biotechnologies reported earnings per share []

Zacks Investment Research downgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a buy rating to a hold rating in a research note published on Tuesday morning, Zacks.com reports. According to Zacks, Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide []

Equities research analysts expect that Adverum Biotechnologies, Inc. (NASDAQ:ADVM) will announce earnings of ($0.42) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Adverum Biotechnologies earnings, with estimates ranging from ($0.43) to ($0.41). Adverum Biotechnologies reported earnings per share of ($0.39) in the same quarter last year, which []

Wall Street analysts predict that Adverum Biotechnologies, Inc. (NASDAQ:ADVM) will announce earnings of ($0.42) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Adverum Biotechnologies earnings, with estimates ranging from ($0.43) to ($0.41). Adverum Biotechnologies posted earnings per share of ($0.39) during the same quarter last []